Artwork

Content provided by medicalminute and Emergency Medical Minute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by medicalminute and Emergency Medical Minute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Podcast # 353: Xofluza

3:25
 
Share
 

Manage episode 212835239 series 1397179
Content provided by medicalminute and Emergency Medical Minute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by medicalminute and Emergency Medical Minute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Author: Sam Killian, MD

Educational Pearls:

  • Japan recently approved baloxavir marboxil (Xofluza), which may potentially "kill" Flu A/B within 24 hours
  • Recent RCT trial showed superiority over oseltamavir (Tamiflu) in cessation of viral shedding (24 vs 72 hours)
  • Compared to placebo, superior in time to symptom resolution (53.7 vs 80.7 hours)
  • Administered as single dose
  • Yet to be considered for FDA approval

References

Portsmouth S, Kawaguchi K, Arai M, Tsuchiya K, Uehara T. Cap-dependent Endonuclease Inhibitor S-033188 for the Treatment of Influenza: Results from a Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study in Otherwise Healthy Adolescents and Adults with Seasonal Influenza. Open Forum Infectious Diseases. 2017;4(Suppl 1):S734. doi:10.1093/ofid/ofx180.001.

  continue reading

1072 episodes

Artwork

Podcast # 353: Xofluza

Emergency Medical Minute

552 subscribers

published

iconShare
 
Manage episode 212835239 series 1397179
Content provided by medicalminute and Emergency Medical Minute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by medicalminute and Emergency Medical Minute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Author: Sam Killian, MD

Educational Pearls:

  • Japan recently approved baloxavir marboxil (Xofluza), which may potentially "kill" Flu A/B within 24 hours
  • Recent RCT trial showed superiority over oseltamavir (Tamiflu) in cessation of viral shedding (24 vs 72 hours)
  • Compared to placebo, superior in time to symptom resolution (53.7 vs 80.7 hours)
  • Administered as single dose
  • Yet to be considered for FDA approval

References

Portsmouth S, Kawaguchi K, Arai M, Tsuchiya K, Uehara T. Cap-dependent Endonuclease Inhibitor S-033188 for the Treatment of Influenza: Results from a Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study in Otherwise Healthy Adolescents and Adults with Seasonal Influenza. Open Forum Infectious Diseases. 2017;4(Suppl 1):S734. doi:10.1093/ofid/ofx180.001.

  continue reading

1072 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide